{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:23:42Z","timestamp":1788362622854,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a potentially curative treatment for high-risk acute myeloid leukemia (AML), and outcomes are strongly influenced by disease status at transplantation. In transplants using conventional graft-versus-host disease (GVHD) prophylaxis, outcomes also depend on the number of induction courses required to achieve first complete remission (CR1); however, this has not been evaluated in patients receiving post-transplant cyclophosphamide (PTCy). We retrospectively analyzed 677 adult AML patients transplanted in CR1 between 2012 and 2022 using PTCy-based GVHD prophylaxis. Outcomes were compared between patients achieving CR1 after one induction course (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009518) and those requiring two courses (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009159). Baseline characteristics, donor type, conditioning intensity, graft source, engraftment, and rates of acute and chronic GVHD were comparable between groups. Patients requiring two inductions had a higher 2-year cumulative incidence of relapse (27% vs. 19.3%; HR 1.75,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.003). However, no significant differences were observed in 2-year overall survival (62.8% vs. 69%), leukemia-free survival (61.1% vs. 65%), GVHD-free\/relapse-free survival (46.3% vs. 50.4%), or non-relapse mortality (11.9% vs. 15.7%). In AML patients receiving alloHSCT with PTCy, outcomes were largely similar regardless of whether CR1 was achieved after one or two-induction courses, with relapse incidence being higher in patients requiring 2 inductions.\n                  <\/jats:p>","DOI":"10.1038\/s41409-026-03012-x","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:08:10Z","timestamp":1788361690000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Allogeneic stem cell transplantation with post-transplantation cyclophosphamide in patients with acute myeloid leukemia achieving first complete remission after one versus two inductions: a study from the ALWP\/EBMT"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0763-1265","authenticated-orcid":false,"given":"Arnon","family":"Nagler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5897-3919","authenticated-orcid":false,"given":"Ryszard","family":"Swoboda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allain Thibeault","family":"Ferhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5684-9447","authenticated-orcid":false,"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2372-1663","authenticated-orcid":false,"given":"Jurjen","family":"Versluis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7327-7834","authenticated-orcid":false,"given":"Gwendolyn","family":"Van Gorkom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maija","family":"Itala-Remes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Colorado Araujo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0543-9592","authenticated-orcid":false,"given":"Helene","family":"Labussiere-Wallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4524-8782","authenticated-orcid":false,"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regis","family":"Peffault de Latour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Gedde-Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieke W. H.","family":"Roeven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8873-2868","authenticated-orcid":false,"given":"Edouard","family":"Forcade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Carr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3142-5581","authenticated-orcid":false,"given":"Patrice","family":"Chevallier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Desmier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Musso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6934-4619","authenticated-orcid":false,"given":"Jaime","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4471-418X","authenticated-orcid":false,"given":"Eolia","family":"Brissot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7171-4997","authenticated-orcid":false,"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-808X","authenticated-orcid":false,"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0873-0123","authenticated-orcid":false,"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"3012_CR1","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.1182\/bloodadvances.2022007168","volume":"6","author":"M Jentzsch","year":"2022","unstructured":"Jentzsch M, Bischof L, Backhaus D, Brauer D, Schulz J, Franke GN, et al. Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission. Blood Adv. 2022;6:4570\u201380. https:\/\/doi.org\/10.1182\/bloodadvances.2022007168.","journal-title":"Blood Adv"},{"key":"3012_CR2","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1111\/bjh.18765","volume":"201","author":"A Nagler","year":"2023","unstructured":"Nagler A, Labopin M, Dholaria B, Blaise D, Bondarenko S, Vydra J, et al. Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remission. Br J Haematol. 2023;201:1169\u201378. https:\/\/doi.org\/10.1111\/bjh.18765.","journal-title":"Br J Haematol"},{"key":"3012_CR3","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","volume":"6","author":"NJ Short","year":"2020","unstructured":"Short NJ, Zhou S, Fu C, Berry DA, Walter RB, Freeman SD, et al. Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis. JAMA Oncol. 2020;6:1890\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2020.4600.","journal-title":"JAMA Oncol"},{"key":"3012_CR4","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","volume":"392","author":"NJ Short","year":"2018","unstructured":"Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392:593\u2013606. https:\/\/doi.org\/10.1016\/S0140-6736(18)31041-9.","journal-title":"Lancet"},{"key":"3012_CR5","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1002\/cncr.35308","volume":"130","author":"J Loke","year":"2024","unstructured":"Loke J, Labopin M, Craddock C, Soci\u00e9 G, Gedde-Dahl T, Blaise D, et al. Prognostic impact of number of induction courses to attain complete remission in patients with acute myeloid leukemia transplanted with either a matched sibling or human leucocyte antigen 10\/10 or 9\/10 unrelated donor: an Acute Leukemia Working Party European Society for Blood and Marrow Transplantation study. Cancer. 2024;130:2642\u201351. https:\/\/doi.org\/10.1002\/cncr.35308.","journal-title":"Cancer"},{"key":"3012_CR6","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/ajh.24062","volume":"90","author":"SJ Lim","year":"2015","unstructured":"Lim SJ, Lim MJ, Raptis A, Hou JZ, Farah R, Marks SM, et al. Inferior outcome after allogeneic transplant in first remission in high-risk AML patients who required more than two cycles of induction therapy. Am J Hematol. 2015;90:715\u20138. https:\/\/doi.org\/10.1002\/ajh.24062.","journal-title":"Am J Hematol"},{"key":"3012_CR7","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41409-021-01537-x","volume":"57","author":"A Nagler","year":"2022","unstructured":"Nagler A, Labopin M, Huang XJ, Blaise D, Arcese W, Araujo MC, et al. Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP\/EBMT. Bone Marrow Transpl. 2022;57:572\u20138. https:\/\/doi.org\/10.1038\/s41409-021-01537-x.","journal-title":"Bone Marrow Transpl"},{"key":"3012_CR8","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/s41409-023-01980-y","volume":"58","author":"A Nagler","year":"2023","unstructured":"Nagler A, Labopin M, Mielke S, Passweg J, Blaise D, Gedde-Dahl T, et al. Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP\/EBMT. Bone Marrow Transpl. 2023;58:791\u2013800. https:\/\/doi.org\/10.1038\/s41409-023-01980-y.","journal-title":"Bone Marrow Transpl"},{"key":"3012_CR9","doi-asserted-by":"publisher","first-page":"5012","DOI":"10.1002\/cncr.25263","volume":"116","author":"JM Rowe","year":"2010","unstructured":"Rowe JM, Kim HT, Cassileth PA, Lazarus HM, Litzow MR, Wiernik PH, et al. Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group. Cancer. 2010;116:5012\u201321. https:\/\/doi.org\/10.1002\/cncr.25263.","journal-title":"Cancer"},{"key":"3012_CR10","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","volume":"14","author":"L Luznik","year":"2008","unstructured":"Luznik L, O\u2019Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose post-transplantation cyclophosphamide. Biol Blood Marrow Transpl. 2008;14:641\u201350.","journal-title":"Biol Blood Marrow Transpl"},{"key":"3012_CR11","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.4049\/jimmunol.145.5.1303","volume":"145","author":"M Eto","year":"1990","unstructured":"Eto M, Mayumi H, Tomita Y, Yoshikai Y, Nishimura Y, Nomoto K. Sequential mechanisms of cyclophosphamide-induced skin allograft tolerance including the intrathymic clonal deletion followed by late breakdown of the clonal deletion. J Immunol. 1990;145:1303\u201310.","journal-title":"J Immunol"},{"key":"3012_CR12","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1080\/16078454.2020.1831292","volume":"25","author":"L Ma","year":"2020","unstructured":"Ma L, Han X, Jiang S, Meng Q, Zhang L, Bao H. Haploidentical stem cell transplantation vs matched unrelated donor transplantation in adults with hematologic malignancies: a systematic review and meta-analysis. Hematology. 2020;25:356\u201365. https:\/\/doi.org\/10.1080\/16078454.2020.1831292.","journal-title":"Hematology"},{"key":"3012_CR13","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1111\/bjh.19825","volume":"205","author":"M Moriguchi","year":"2024","unstructured":"Moriguchi M, Nakamae H, Nishimoto M, Sugita J, Yanada M, Toubai T, et al. Comparison of HLA-haploidentical donors with post-transplant cyclophosphamide versus HLA-matched unrelated donors in peripheral blood stem cell transplantation for acute myeloid leukaemia. Br J Haematol. 2024;205:2376\u201386. https:\/\/doi.org\/10.1111\/bjh.19825.","journal-title":"Br J Haematol"},{"key":"3012_CR14","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1002\/ajh.70069","volume":"100","author":"Y Ru","year":"2025","unstructured":"Ru Y, Chen J, Ferhat AT, Labussi\u00e8re-Wallet H, Gedde-Dahl T, Kr\u00f6ger N, et al. Similar outcome with haploidentical, matched sibling, or matched unrelated donor hematopoietic cell transplantation for adult patients with adverse-risk TP53-mutated acute myeloid leukemia in first remission. Am J Hematol. 2025;100:2220\u20139. https:\/\/doi.org\/10.1002\/ajh.70069.","journal-title":"Am J Hematol"},{"key":"3012_CR15","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1158\/1078-0432.CCR-20-2809","volume":"27","author":"A Nagler","year":"2021","unstructured":"Nagler A, Labopin M, Dholaria B, Angelucci E, Afanasyev B, Cornelissen JJ, et al. Comparison of haploidentical bone marrow versus matched unrelated donor peripheral blood stem cell transplantation with posttransplant cyclophosphamide in patients with acute leukemia. Clin Cancer Res. 2021;27:843\u201351. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2809.","journal-title":"Clin Cancer Res"},{"key":"3012_CR16","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41409-022-01577-x","volume":"57","author":"G Battipaglia","year":"2022","unstructured":"Battipaglia G, Galimard JE, Labopin M, Raiola AM, Blaise D, Ruggeri A, et al. Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT. Bone Marrow Transpl. 2022;57:562\u201371. https:\/\/doi.org\/10.1038\/s41409-022-01577-x.","journal-title":"Bone Marrow Transpl"},{"key":"3012_CR17","doi-asserted-by":"publisher","first-page":"2772","DOI":"10.1200\/JCO-25-00856","volume":"43","author":"MM Al Malki","year":"2025","unstructured":"Al Malki MM, Bo-Subait S, Logan B, Olson J, Kou J, Smith S, et al. post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis after mismatched unrelated donor peripheral blood stem cell transplantation. J Clin Oncol. 2025;43:2772\u201381. https:\/\/doi.org\/10.1200\/JCO-25-00856.","journal-title":"J Clin Oncol"},{"key":"3012_CR18","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1200\/JCO.24.00184","volume":"42","author":"BC Shaffer","year":"2024","unstructured":"Shaffer BC, Gooptu M, DeFor TE, Maiers M, Bola\u00f1os-Meade J, Abboud R, et al. post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis attenuates disparity in outcomes between use of matched or mismatched unrelated donors. J Clin Oncol. 2024;42:3277\u201386. https:\/\/doi.org\/10.1200\/JCO.24.00184.","journal-title":"J Clin Oncol"},{"key":"3012_CR19","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1038\/s41375-024-02225-7","volume":"38","author":"O Penack","year":"2024","unstructured":"Penack O, Abouqateb M, Peczynski C, Boreland W, Kr\u00f6ger N, Stelljes M, et al. ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation? Leukemia. 2024;38:1156\u201363. https:\/\/doi.org\/10.1038\/s41375-024-02225-7.","journal-title":"Leukemia"},{"key":"3012_CR20","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13045-020-00882-6","volume":"13","author":"J Sanz","year":"2020","unstructured":"Sanz J, Galimard JE, Labopin M, Afanasyev B, Angelucci E, Ciceri F, et al. Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. J Hematol Oncol. 2020;13:46 https:\/\/doi.org\/10.1186\/s13045-020-00882-6.","journal-title":"J Hematol Oncol"},{"key":"3012_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00990-3","volume":"14","author":"E Brissot","year":"2024","unstructured":"Brissot E, Labopin M, Labussi\u00e8re H, Fossard G, Chevallier P, Guillaume T, et al. Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10\/10 HLA-matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial. Blood Cancer J. 2024;14:31. https:\/\/doi.org\/10.1038\/s41408-024-00990-3.","journal-title":"Blood Cancer J"},{"key":"3012_CR22","first-page":"208.e1","volume":"29","author":"BE Shaw","year":"2023","unstructured":"Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, et al. Three-year outcomes in recipients of mismatched unrelated bone marrow donor transplants using post-transplantation cyclophosphamide: follow-up from a national marrow donor program-sponsored prospective clinical trial. Transpl Cell Ther. 2023;29:208.e1\u2013208.e6.","journal-title":"Transpl Cell Ther"},{"key":"3012_CR23","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","volume":"388","author":"J Bola\u00f1os-Meade","year":"2023","unstructured":"Bola\u00f1os-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, et al. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023;388:2338\u201348.","journal-title":"N Engl J Med"},{"key":"3012_CR24","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1182\/bloodadvances.2025015964","volume":"9","author":"S Abedin","year":"2025","unstructured":"Abedin S, Martens MJ, Bola\u00f1os-Meade J, Al Malki MM, Lian Q, Runaas L, et al. Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703. Blood Adv. 2025;9:3495\u2013501.","journal-title":"Blood Adv"},{"key":"3012_CR25","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl. 2009;15:1628\u201333.","journal-title":"Biol Blood Marrow Transpl"},{"key":"3012_CR26","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. Consensus conference on acute GVHD grading. Bone Marrow Transpl. 1995;15:825\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"3012_CR27","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","volume":"69","author":"HM Shulman","year":"1980","unstructured":"Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204\u201317.","journal-title":"Am J Med"},{"key":"3012_CR28","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/bmt.2015.305","volume":"51","author":"A Ruggeri","year":"2016","unstructured":"Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transpl. 2016;51:610\u20131.","journal-title":"Bone Marrow Transpl"},{"key":"3012_CR29","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2991\/chi.d.191207.001","volume":"2","author":"AS Kanate","year":"2019","unstructured":"Kanate AS, Nagler A, Savani B. Summary of scientific and statistical methods, study endpoints and definitions for observational and registry-based studies in hematopoietic cell transplantation. Clin Hematol Int. 2019;2:2\u20134.","journal-title":"Clin Hematol Int"},{"key":"3012_CR30","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.bbmt.2014.09.022","volume":"21","author":"RB Walter","year":"2015","unstructured":"Walter RB, Sandmaier BM, Storer BE, Godwin CD, Buckley SA, Pagel JM, et al. Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission. Biol Blood Marrow Transpl. 2015;21:373\u20138. https:\/\/doi.org\/10.1016\/j.bbmt.2014.09.022.","journal-title":"Biol Blood Marrow Transpl"},{"key":"3012_CR31","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1038\/s41375-022-01738-3","volume":"37","author":"M Boyiadzis","year":"2023","unstructured":"Boyiadzis M, Zhang MJ, Chen K, Abdel-Azim H, Abid MB, Aljurf M, et al. Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients. Leukemia. 2023;37:1006\u201317. https:\/\/doi.org\/10.1038\/s41375-022-01738-3.","journal-title":"Leukemia"},{"key":"3012_CR32","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41375-024-02445-x","volume":"39","author":"A Shimoni","year":"2025","unstructured":"Shimoni A, Peczynski C, Labopin M, Kulagin A, Meijer E, Cornelissen J, et al. Post-transplant cyclophosphamide separates graft-versus host disease and graft versus leukemia effects after HLA-matched stem-cell transplantation for acute myeloid leukemia. Leukemia. 2025;39:222\u20138.","journal-title":"Leukemia"},{"key":"3012_CR33","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13045-023-01403-x","volume":"16","author":"F Baron","year":"2023","unstructured":"Baron F, Labopin M, Tischer J, Raiola AM, Vydra J, Blaise D, et al. GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT. J Hematol Oncol. 2023;16:10.","journal-title":"J Hematol Oncol"},{"key":"3012_CR34","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1111\/bjh.70101","volume":"207","author":"A Shimoni","year":"2025","unstructured":"Shimoni A, Peczynski C, Labopin M, Dominietto A, Koc M, Arat M, et al. Graft-versus-host disease is not associated with reduced incidence of relapse following haploidentical stem cell transplantation with post-transplant cyclophosphamide for acute lymphoblastic leukaemia: A study on behalf of the Acute Leukaemia Working Party of European Society for Blood and Marrow Transplantation. Br J Haematol. 2025;207:2041\u20138.","journal-title":"Br J Haematol"},{"key":"3012_CR35","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1038\/s41409-022-01742-2","volume":"57","author":"A Nagler","year":"2022","unstructured":"Nagler A, Labopin M, Cornelissen JJ, Forcade E, Chevallier P, Fegueux N, et al. Outcome of human umbilical cord blood stem cell transplantation for acute myeloid leukemia in patients achieving first complete remission after one versus two induction courses: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transpl. 2022;57:1514\u20139. https:\/\/doi.org\/10.1038\/s41409-022-01742-2.","journal-title":"Bone Marrow Transpl"},{"key":"3012_CR36","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1056\/NEJMoa1602074","volume":"375","author":"F Milano","year":"2016","unstructured":"Milano F, Gooley T, Wood B, Woolfrey A, Flowers ME, Doney K, et al. Cord-blood transplantation in patients with minimal residual disease. N Engl J Med. 2016;375:944\u201353.","journal-title":"N Engl J Med"},{"key":"3012_CR37","doi-asserted-by":"publisher","first-page":"4425","DOI":"10.1182\/bloodadvances.2025015938","volume":"9","author":"R Wynn","year":"2025","unstructured":"Wynn R, Volt F, Guardiola P, Senthil S, Scigliuolo G, Kenzey C, et al. Impact of shared HLA determinants between patient and losing cord blood unit on relapse after double cord blood transplantation. Blood Adv. 2025;9:4425\u201335.","journal-title":"Blood Adv"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03012-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03012-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03012-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:08:12Z","timestamp":1788361692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03012-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":37,"alternative-id":["3012"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-03012-x","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"7 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no relevant competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. The scientific boards of the ALWP of the EBMT approved this study. Informed consent was obtained from all subjects.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}